Jupiter Neurosciences, Inc. has a market cap of $131.5 million and held its IPO with underwriters Dominari Securities and Revere Securities.
This company is focused on developing JOTROL, a special resveratrol product aimed at treating neuro-inflammation, primarily for diseases like Parkinson’s and Mild Cognitive Impairment. JOTROL uses a patented micellar technology that aims to enhance the bioavailability of resveratrol. The company completed a Phase I clinical trial in 2021, showing promising results to support future trials.
Future plans include launching a Phase II clinical trial for Parkinson’s Disease using the funds raised from the IPO. They have also formed agreements to expand into South-East Asia, particularly for the treatment of rare diseases linked to JOTROL.
The company believes JOTROL can be effective without common gastrointestinal side effects seen in other resveratrol products, based on preclinical results and previous research. Notably, they secured $1.76 million funding from the National Institute on Aging for their Phase I study.
Founded in 2016, Jupiter Neurosciences is based in Florida and currently has four employees. For more information, visit their website.
Stay updated on Jupiter Neurosciences Inc.! Enter your email below for daily news and ratings summaries from MarketBeat.com’s FREE daily email newsletter.
`
